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Case Reports 
Invasive pulmonary aspergillosis with 
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intravenous corticosteroid therapy in a patient with 
asthma 
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The present case report describes a case of invasive pulmonary aspergillosis with cerebromeningeal 
invasion in an asthmatic non-immunocompromised patient. This fatal complication occurred despite 
early anti-fungal antibiotherapy after a 2-week course of intravenous corticosteroid therapy for 
treatment of an exacerbated asthma. Diagnostic and therapeutic procedures are discussed. 
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Introduction 
Invasive pulmonary aspergillosis (IPA) has been rec- 
ognized as an infectious complication occurring 
almost exclusively in immunocompromised or neu- 
tropenic patients. Other predisposing risk factors 
include alcoholism, diabetes, broad spectrum 
parenteral antibiotics and long-term corticosteroid 
therapy (1). Several cases have been reported in 
non-immunocompromised patients with chest dis- 
eases such as chronic bronchitis (2) and pulmonary 
infections (viral, Mycoplasma pneumoniae, Legion- 
nella). Very few reports of invasive pulmonary 
aspergillosis have been published in asthmatic 
patients (3-5). The present case report describes a 
case of IPA with cerebromeningeal invasion in an 
asthmatic patient, in which the only risk factor was 
short-term intravenous (i.v.) corticosteroid therapy. 
Received 26 December 1995 and accepted in revised form 
1 August 1996. 
Correspondence should be addressed to: G. Pauli, Service 
de Pneumologie, Hopital Civil, Hopitaux Universitaires de 
Strasbourg, BP 426, F-67091 Strasbourg, Cedex, France. 
0954.6111/97/070435 f03 $12.00/O 
Case Report 
A 75-year-old asthmatic woman was admitted to the 
Chest Diseases Department with an asthma attack on 
7 January. The patient had a history of untreated 
Parkinson’s disease and 30 yr of asthma. For several 
years, she had been treated with salbutamol by 
metered aerosol, beclometasone dipropionate (500 yg 
three times per day) and oral sustained-release theo- 
phylline (175 mg twice per day). On admission, she 
had fever (38°C) and mild tachypnoea (peak 
flow= 140 1 min- ‘). Examination showed bilateral 
wheezing but no evidence of consolidation. The 
erythrocyte sedimentation rate was 42 mm- ‘; the 
C-reactive protein was 10 mg 1 - ‘; the white cell count 
was 9130 with 77% neutrophils; the platelet count was 
244 000 l- I; and the serum theophylline concen- 
tration was 10.8 mg 1 - ‘. While breathing room air, 
the arterial blood gas analysis showed: pH=7.48; 
PaO, = 65 mmHg; PaCO, = 3 1 mmHg; HCO, = 
24mmoll-‘; and SaO,=93.8%. The pulmonary 
function data demonstrated severe bronchial obstruc- 
tion: forced expiratory volume in 1s (FEV,)=925 ml 
(61% of predicted value); and vital capacity 
(VC)=2350 ml (102% of predicted value). The chest 
X-rays disclosed evidence of consolidation. Initial 
serologic tests (8 January) for aspergillus antibodies 
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PLATE 1. On the 15th hospital day, chest X-ray 
reveals diffuse nodular densities throughout both 
lung fields. 
were negative. Amoxicilline (3 g i.v. day- ’ and meth- 
ylprednisolone (120 mg i.v. day - ‘) were added to the 
previous treatment. The temperature decreased to 
37°C within 1 day and the respiratory symptoms 
improved initially. The corticosteroid therapy was 
reduced to 80 mg after 8 days, and to 40 mg after 14 
days. However, the patient still had wheezes and no 
clear sputum. During the first week of her hospital- 
ization, a new floor covering was laid down in the 
corridor. On the 15th hospital day (24 January), her 
temperature increased to 38.K and chest X-rays 
revealed diffuse nodular densities throughout both 
lung fields (Plate 1). Sputum examinations and 
bronchoalveolar lavage (BAL) showed Aspergillus 
jiimigatus and Acinetobacter baumanii (Acb 8 x lo3 
CFU ml - ‘), but blood cultures remained sterile. The 
histologic examination of endobronchial biopsy 
specimens was normal. Precipitating antibodies to 
A. fumigatus were found positive using immuno- 
electrophoresis [four bands with (-I-) catalase activity 
on 22 January and seven bands on 27 January]. 
Paired titers of antibodies to Mycoplasma pneumonia, 
Legionnella pneumophila and a range of pulmonary 
viral pathogens showed no appreciable rise, and 
screening for human immunodeficiency virus gave a 
negative result. Antibiotic treatment was changed: 
imipenem (0.5 g i.v. every 8 h), pefloxacine (400 mg 
i.v. every 12 h), and vancomycine (0.5 g i.v. every 
8 h - ‘). Amphotericin B was also immediately started 
at a dosage of 0.6 mg kg - ’ i.v. on the first day and 
1 mgkg-’ afterwards. Nevertheless, she developed 
PLATE 2. Necrotizing granuloma in the lung (hae- 
matoxylin and eosin x 160); note the presence of 
Aspergillus hyphae and vascular invasion. 
acute respiratory failure with worsening hypoxaemia 
which required mechanical ventilation on the 20th 
day. 5-Fluorocytosine (100 mg kg- ’ iv. day) was 
added to the previous treatment. The patient’s condi- 
tion deteriorated progressively and on the 22nd hos- 
pital day, she developed multiple organ failure, with 
septic shock and left haemiplegia. Serial chest X-rays 
showed worsening consolidation; tracheal aspirations 
remained positive for A. jiimigatus and the serologic 
tests were unchanged. The patient died on the 26th 
hospital day. The total dose of amphotericin B 
administrated was 0.5 g. Autopsy showed heavy and 
hyperhaemic lungs with confluent abscesses. Histo- 
logic examination showed abscesses containing 
numerous Aspergillus hyphae with vascular invasion 
(Plate 2). Brain examination revealed a right haemor- 
ragic infarct with subcortical blood vessel invasion 
and meningeal diffusion by Aspergillus fungi. Liver, 
spleen and bone marrow were normal. 
Discussion 
A rapidly fatal IPA occurred in the course of treat- 
ment of an exacerbation of asthma in this non- 
neutropenic, non-immunocompromised patient. In 
recent years, several authors have reported invasive 
pulmonary aspergillosis in non-immunocompromised 
adults and children (2,6,7). The corticosteroid 
therapy, even in short-term parenteral admin- 
istration, was probably a risk factor in this patient. 
The pathogenesis of the fungal infection was primar- 
ily thought to be due to the inhibitory effect of 
corticosteroids on the monocyte-mediated damage to 
fungal hyphae (8) and the conicidal activity of tissue 
macrophages (9). Moreover, it has recently been 
shown that hydrocortisone could enhance growth of 
Aspergillus species (10). 
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The pre-hospital treatment of the present patient 
was inhaled steroids, but it seems very doubtful that 
this treatment could be responsible for the IPA. The 
patient had no fungal hyphae in sputum at the 
beginning of hospitalization. However, a case of IPA 
has been reported in an 8 l-year-old man in whom the 
only risk factor was treatment with inhaled steroids 
prior to a short-term oral corticosteroid therapy (5). 
Morton et al. (3) described a case of a 16-year-old girl 
who developed aspergillus lung abscesses, but this 
patient had evidence of malnutrition and signs of 
long-term high-dose corticosteroids. Lake et al. (4) 
reported a case in which the principal risk factor was 
a short-term, high-dose (i.e. 320-120 mg methylpred- 
nisolone day - ‘) . . i v corticosteroid course; as in the 
present patient, fatal disseminated aspergillosis 
occurred. At autopsy, diffuse abscess formation 
throughout both lungs was found. The authors 
suggested that a mycoplasma infection could have 
been an additional risk factor for the development of 
IPA. In the present case, high exposure to aspergillus 
which may occur during building renovation could 
have been an initiating factor for the development of 
IPA. Since no measurements of exposure to asper- 
gillus during the renovation were available, one can 
suppose that heavy exposure to aspergillus is the most 
important factor of IPA in the present patient. 
Recently, the present authors reported two other 
cases of IPA in two non-immunocompromised 
patients after massive exposure to aspergillus; both 
recovered after treatment (11). It has been shown that 
in non-immunocompromised and healthy persons, 
fatal acute pulmonary aspergillosis can occur after 
heavy exposure to aspergillus in an agricultural 
environment (12,13). 
The main clinical feature of the case reported and 
of other cases in non-compromised subjects in the 
literature is a rapidly developing bronchopneumonia 
resulting in death due to respiratory failure. The 
multinodular opacities corresponding to micro- 
abscesses can mimic staphylococci pneumonia or 
Wegener’s granulomatosis. The treatment of choice is 
intravenous amphotericin B. However, conventional 
therapeutic doses are often inefficient and one can 
suppose that administration of higher doses using 
liposomal amphotericin B could perhaps modify the 
very severe prognosis of this disease (14). 
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